Published in Endocr Connect on November 01, 2017
Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med (2016) 2.99
Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can (2008) 1.96
The detection, investigation and management of hypertension in pregnancy: full consensus statement. Aust N Z J Obstet Gynaecol (2000) 1.75
Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev (2014) 1.05
Matrix metalloproteinase-9 deficiency phenocopies features of preeclampsia and intrauterine growth restriction. Proc Natl Acad Sci U S A (2013) 0.99
Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J Clin Lab Anal (2009) 0.99
Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev (2013) 0.96
Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ (1997) 0.96
Nifedipine in the treatment of severe preeclampsia. Obstet Gynecol (1991) 0.94
Effects of resveratrol in pregnancy using murine models with reduced blood supply to the uterus. PLoS One (2013) 0.87
Matrix metalloproteinases as drug targets in preeclampsia. Curr Drug Targets (2013) 0.85
Influence of the sFlt-1/PlGF Ratio on Clinical Decision-Making in Women with Suspected Preeclampsia. PLoS One (2016) 0.84
Resveratrol and Cardiovascular Diseases. Nutrients (2016) 0.84
Resveratrol inhibits trophoblast apoptosis through oxidative stress in preeclampsia-model rats. Molecules (2014) 0.83
Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia. Acta Obstet Gynecol Scand (2002) 0.83
Nifedipine in myocardial ischemia, systemic hypertension, and other cardiovascular disorders. Ann Intern Med (1986) 0.83
Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia. Reprod Biol Endocrinol (2009) 0.82
The effect of resveratrol on blood pressure in a rat model of preeclampsia. J Matern Fetal Neonatal Med (2011) 0.82
Resveratrol inhibits the release of soluble fms-like tyrosine kinase (sFlt-1) from human placenta. Am J Obstet Gynecol (2011) 0.81
Resveratrol inhibits matrix metalloproteinases to attenuate neuronal damage in cerebral ischemia: a molecular docking study exploring possible neuroprotection. Neural Regen Res (2015) 0.80
Nifedipine and its indications in obstetrics and gynecology. Obstet Gynecol (1994) 0.79
Resveratrol attenuates matrix metalloproteinase-9 and -2-regulated differentiation of HTB94 chondrosarcoma cells through the p38 kinase and JNK pathways. Oncol Rep (2014) 0.79
The use of nifedipine during the postpartum period in patients with severe preeclampsia. Am J Obstet Gynecol (1990) 0.79
Resveratrol improves delayed r-tPA treatment outcome by reducing MMPs. Acta Neurol Scand (2015) 0.78
Development of preeclampsia within four weeks of sFLT to PLGF ratio >38: Comparison of performance at 31-34 versus 35-37 weeks' gestation. Ultrasound Obstet Gynecol (2016) 0.78
Resveratrol lowers blood pressure in spontaneously hypertensive rats via calcium-dependent endothelial NO production. Clin Exp Hypertens (2016) 0.77
Resveratrol reduces matrix metalloproteinases and alleviates intrahepatic cholestasis of pregnancy in rats. Can J Physiol Pharmacol (2015) 0.77
Budget impact analysis of sFlt-1/PlGF ratio as prediction test in Italian women with suspected preeclampsia. J Matern Fetal Neonatal Med (2016) 0.77
sFlt-1/PlGF ratio test for pre-eclampsia: an economic assessment for the UK. Ultrasound Obstet Gynecol (2016) 0.77
sFlt-1/PlGF for early-onset pre-eclampsia prediction: STEPS (Study of Early Pre-eclampsia in Spain). Ultrasound Obstet Gynecol (2016) 0.77
Ketanserin versus dihydralazine for the treatment of severe hypertension in early-onset preeclampsia: a double blind randomized controlled trial. Eur J Obstet Gynecol Reprod Biol (2015) 0.77
Oral nifedipine versus intravenous labetalol for the treatment of severe hypertension in pregnancy. Int J Cardiol (2014) 0.77
A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy. Semin Perinatol (2015) 0.77
Nifedipine versus labetalol in the treatment of hypertensive disorders of pregnancy. Arch Gynecol Obstet (2012) 0.76
Hemodynamic changes associated with intravenous infusion of the calcium antagonist verapamil in the treatment of severe gestational proteinuric hypertension. Obstet Gynecol (1990) 0.76
Resveratrol ameliorates the chemical and microbial induction of inflammation and insulin resistance in human placenta, adipose tissue and skeletal muscle. PLoS One (2017) 0.75
The effect of resveratrol on hypertension: A clinical trial. Exp Ther Med (2016) 0.75